Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Milestone Pharmaceuticals Inc. MIST
$4.33
+$0.08 (1.88%)
На 18:01, 12 мая 2023
+130.95%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
137815622.00000000
-
week52high
9.85
-
week52low
3.10
-
Revenue
5000000
-
P/E TTM
-6
-
Beta
2.02221400
-
EPS
-1.33000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Neutral | 22 апр 2022 г. |
| HC Wainwright & Co. | Buy | 05 мар 2021 г. | |
| Oppenheimer | Outperform | Perform | 29 июл 2020 г. |
| Jefferies | Buy | Hold | 24 июл 2020 г. |
| Jefferies | Hold | Buy | 25 мар 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 14 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bharucha David | A | 10000 | 7000 | 05 дек 2022 г. |
| Bharucha David | A | 3000 | 3000 | 01 дек 2022 г. |
| Liebert Debra K. | A | 4000 | 4000 | 21 окт 2022 г. |
| Pasternak Richard C | A | 10000 | 10000 | 20 окт 2022 г. |
| Liebert Debra K. | A | 10000 | 10000 | 20 окт 2022 г. |
| Wills Robert James | A | 15000 | 15000 | 19 окт 2022 г. |
| TOMSICEK MICHAEL JOHN | A | 15000 | 15000 | 19 окт 2022 г. |
| Liebert Debra K. | A | 127 | 127 | 14 сент 2022 г. |
| RTW INVESTMENTS, LP | D | 4315102 | 1557346 | 07 сент 2022 г. |
| RTW INVESTMENTS, LP | A | 4315102 | 1557346 | 07 сент 2022 г. |
Новостная лента
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Zacks Investment Research
16 янв 2023 г. в 13:33
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
Zacks Investment Research
13 дек 2022 г. в 11:17
The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
PennyStocks
14 ноя 2022 г. в 13:33
Analysts say these are penny stocks to buy. Do you agree?
Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023
Seeking Alpha
05 ноя 2022 г. в 02:28
Etripamil succeeded in phase 3 RAPID study, Milestone in talks with FDA to possibly file an NDA for this drug in treating PSVT patients by mid-2023. It is said that there are about 2 million PSVT patients in the United States currently.
Milestone Pharmaceuticals: Looking Attractive After Drop On Positive News
Seeking Alpha
30 окт 2022 г. в 07:25
Milestone Pharmaceuticals reported positive data from the RAPID arm of its pivotal trial. After an initial premarket spurt, the stock dropped drastically.